Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global reportBorisov Se, Valentina Marchese, Skaidrius Miliauskas et al.|European Respiratory Journal|2019Cited by 176
Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort studyOleksandr Korotych, Askar Yedilbayev, Jay Achar et al.|The Lancet Infectious Diseases|2024Cited by 23